Proprotein convertase subtilisin/kexin type 9 inhibitors: a turning point in HIV-associated dyslipidemia?

AIDS. 2022 Apr 1;36(5):745-747. doi: 10.1097/QAD.0000000000003150.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Dyslipidemias*
  • HIV Infections* / complications
  • HIV Infections* / drug therapy
  • Humans
  • Proprotein Convertase 9
  • Subtilisin

Substances

  • Proprotein Convertase 9
  • Subtilisin